Shares of BioNTech (NASDAQ:BNTX) were down nearly 7% today after two studies of more than 50,000 patients in the Mayo Clinic Health System showed rival Modernas (NASDAQ:MRNA) vaccine might be more effective against the troublesome delta variant of the SARS-CoV-2 coronavirus.
The effectiveness of BioNTechs vaccine, developed with Pfizer (NYSE:PFE), was only 42% during July, according to the study, compared to 76% for Moderna. The numbers were calculated at a time that delta has become the dominant strain infecting Americans. A second study showed nursing home residents generated stronger immune responses after the Moderna vaccine than after BioNTechs.
Image source: Getty Images.
With so many Americans already vaccinated, the study wont have as much impact as it might have had if it came out earlier this year. Still, it might sway those who remain unvaccinated to seek out the Moderna jab over BioNTechs. There are still more than 700,000 vaccinations happening per day, enough to move the needle financially.
It may also impact the demand for boosters. Despite the hesitancy of the Food and Drug Administration and the Centers for Disease Control and Prevention, there is little doubt that additional shots to maintain immunity will be necessary. Its been reported that the agencies could authorize them for the 7 million immunocompromised Americans as soon as this month.
The move today couldnt have been all about the data, though. Moderna shares fell almost 6%. Investors will need to watch for any updates as the studies go to peer review. As it stands, Moderna and BioNTech expect $20 billion and $18.6 billion, respectively, in vaccine revenue this year.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.Jason Hawthorne owns shares of BioNTech SE. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.>
Motley Fool Returns
Stock Advisor S&P 500
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 08/31/2021.
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return
Find us at the office
Schwede- Busard street no. 40, 77937 Riyadh, Saudi Arabia
Give us a ring
+86 488 682 876
Mon - Fri, 10:00-17:00